Given the pivotal role of IL‐6 signalling in CRS and its prognostic significance in COVID‐19,40 there has been considerable interest in the therapeutic potential of the IL‐6 receptor antagonist, tocilizumab. Here, IL6 is linked to congenital rubella syndrome.